MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.68 -1.47

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.67

Max

2.73

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5.9M

247K

Pardavimai

5.1M

62M

Pelno marža

0.395

Darbuotojai

181

EBITDA

-6.1M

7.4M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+156.41% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-162M

726M

Ankstesnė atidarymo kaina

4.15

Ankstesnė uždarymo kaina

2.68

Naujienos nuotaikos

By Acuity

94%

6%

356 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Akebia Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-30 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

2025-09-30 23:43; UTC

Karštos akcijos

Stocks to Watch: GEO Group, Lithium Americas, Nike

2025-09-30 23:12; UTC

Uždarbis

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

2025-09-30 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Lifeway Foods, Danone Agree to Stay Litigation -- Update

2025-09-30 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Lifeway Foods, Danone Agree to Stay Litigation

2025-09-30 21:17; UTC

Uždarbis

Nike 1Q Sales Rise as Turnaround Progresses -- Update

2025-09-30 20:47; UTC

Uždarbis

Nike 1Q Sales Rise as Turnaround Progresses

2025-09-30 23:45; UTC

Rinkos pokalbiai

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

2025-09-30 23:45; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

2025-09-30 23:26; UTC

Įsigijimai, susijungimai, perėmimai

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

2025-09-30 23:26; UTC

Įsigijimai, susijungimai, perėmimai

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

2025-09-30 23:25; UTC

Įsigijimai, susijungimai, perėmimai

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

2025-09-30 23:24; UTC

Įsigijimai, susijungimai, perėmimai

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

2025-09-30 23:24; UTC

Įsigijimai, susijungimai, perėmimai

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

2025-09-30 22:54; UTC

Rinkos pokalbiai

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

2025-09-30 22:38; UTC

Uždarbis

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

2025-09-30 22:32; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-30 22:32; UTC

Rinkos pokalbiai

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

2025-09-30 22:03; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

2025-09-30 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

2025-09-30 21:02; UTC

Uždarbis

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

2025-09-30 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-09-30 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-09-30 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-30 20:28; UTC

Uždarbis

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

2025-09-30 20:22; UTC

Uždarbis

Nike 1Q North America Revenue $5.02B >NKE

2025-09-30 20:22; UTC

Uždarbis

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

2025-09-30 20:22; UTC

Uždarbis

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

2025-09-30 20:22; UTC

Uždarbis

Nike 1Q Greater China Revenue $1.51B >NKE

2025-09-30 20:19; UTC

Uždarbis

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Akcijų palyginimas

Kainos pokytis

Akebia Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

156.41% į viršų

12 mėnesių prognozė

Vidutinis 7 USD  156.41%

Aukščiausias 8 USD

Žemiausias 6 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Akebia Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

2.345 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

356 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat